Evidence map›Paper›PMID 32716358›Full record

Trial reportJournal of Alzheimer's disease : JAD2020

Baseline Prevalence of Polypharmacy in Older Hypertensive Study Subjects with Elevated Dementia Risk: Findings from the Risk Reduction for Alzheimer's Disease Study (rrAD).

Eric D Vidoni, Ashwini Kamat, William P Gahan, Victoria Ourso, Kaylee Woodard, Diana R Kerwin, Ellen F Binder, Jeffrey M Burns, Munro Cullum, Linda S Hynan and 4 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of Alzheimer's disease : JAD, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Eric D VidoniKU Alzheimer's Disease Center, Fairway KS, USA.
Ashwini KamatKU Alzheimer's Disease Center, Fairway KS, USA.
William P GahanPennington Biomedical Research Center, Baton Rouge, LA, USA.
Victoria OursoPennington Biomedical Research Center, Baton Rouge, LA, USA.
Kaylee WoodardPennington Biomedical Research Center, Baton Rouge, LA, USA.
Diana R KerwinDepartment of Neurology & Neurotherapeutics, UT Southwestern Medical Center, Dallas, TX, USA.
Ellen F BinderDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Jeffrey M BurnsKU Alzheimer's Disease Center, Fairway KS, USA.
Munro CullumDepartment of Neurology & Neurotherapeutics, UT Southwestern Medical Center, Dallas, TX, USA.
Linda S HynanDepartment of Neurology & Neurotherapeutics, UT Southwestern Medical Center, Dallas, TX, USA.
Wanpen VongpatanasinDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
David C ZhuDepartment of Radiology and Cognitive Imaging Research Center, Michigan State University, East Lansing, MI, USA.
Rong ZhangDepartment of Neurology & Neurotherapeutics, UT Southwestern Medical Center, Dallas, TX, USA.
Jeffrey N KellerPennington Biomedical Research Center, Baton Rouge, LA, USA.
Pennington Biomedical Research Center · USSouthwestern Medical CenterSouthwestern Medical Center · USUniversity of Kansas Medical Center · USMichigan State University · USThe University of Texas Southwestern Medical Center · USWashington University in St. Louis · US

Funding

University of Kansas Alzheimer's Disease Research Center (KU ADRC)P30AG072973 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Jaime Perales Puchalt · 2021 to 2026
$25.3M
University of Kansas Alzheimer's Disease Core CentersP30AG035982 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BROOKS, WILLIAM M. · 2011 to 2020
$16.6M
Exercise and Intensive Vascular Risk Reduction in Preventing DementiaR01AG049749 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI BINDER, ELLEN F, BURNS, JEFFREY MURRAY · 2016 to 2020
$15.1M
NIA NIH HHS P30 AG035982NIA NIH HHS P30 AG072973NIA NIH HHS R01 AG049749
6 · The paper itself

Abstract

backgroundLittle is known about the prevalence of polypharmacy, the taking of five or more medications a day, in older adults with specific dementia risk factors.

objectiveTo examine the prevalence of polypharmacy in participants at baseline in a vascular risk reduction focused Alzheimer's disease (rrAD) trial targeting older patients with hypertension and elevated dementia risk.

methodsWe conducted a detailed review of medications in a cross-sectional study of community-dwelling older adults with hypertension and elevated dementia risk. Medications were identified in a structured interview process with an onsite pharmacist or qualified designee. Polypharmacy was defined as use of five or more medications on a regular basis. Descriptive analyses were conducted on the sample as well as direct comparisons of subgroups of individuals with hypertension, diabetes, and hyperlipidemia.

resultsThe 514 rrAD participants, mean age 68.8 (standard deviation [sd] 6), reported taking different combinations of 472 unique medications at their baseline visit. The median number of medications taken by participants was eight [Range 0-21], with 79.2% exhibiting polypharmacy (n = 407). Sites differed in their prevalence of polypharmacy, χ2(3) = 56.0, p < 0.001. A nearly identical percentage of the 2,077 prescribed (51.8%) and over the counter (48.2%) medications were present in the overall medication profile. The presence of diabetes (87.5%), hyperlipidemia (88.2%), or both (97.7%) was associated with a higher prevalence of polypharmacy than participants who exhibited hypertension in the absence of either of these conditions (63.2%), χ2(3) = 35.8, p < 0.001.

conclusionParticipants in a dementia risk study had high levels of polypharmacy, with the co-existence of diabetes or hyperlipidemia associated with a greater prevalence of polypharmacy as compared to having hypertension alone.

Indexed as

PolypharmacyAgedAged, 80 and overAlzheimer DiseaseAntihypertensive AgentsCross-Sectional StudiesDementiaDiabetes MellitusFemaleHumansHypertensionMaleMedication ReconciliationMiddle AgedPrevalenceRisk FactorsAntihypertensive AgentsAlzheimer’s diseasedementiahypertensioninappropriate medicationpolypharmacyrisk factor

Identifiers

PMID32716358
PMCPMC8108402
OpenAlexW3044204393

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.